BioSpace News Archive

Genetown

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio, a clinical-stage cell and genome engineering company, presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia.

November 9, 2023
·
8 min read
Biotech Bay

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Lyell Immunopharma, Inc. (Nasdaq: LYEL) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte (TIL) product candidate for the treatment of patients with stage IIB-IV melanoma.

November 9, 2023
·
7 min read
Business

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.

November 9, 2023
·
11 min read
Business

Sensus Healthcare Reports Third Quarter 2023 Financial Results

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2023.

November 9, 2023
·
15 min read
Business

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Jasper Therapeutics, Inc. today announced results for the fiscal quarter ended September 30, 2023, and provided a business update.

November 9, 2023
·
10 min read
Genetown

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

Fulcrum Therapeutics, Inc. today announced that management will participate in the following upcoming investor conferences.

November 9, 2023
·
1 min read
Lunit Expands Reach of its AI-Powered Chest Screening Solution to Global Military Health Institutions

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced the successful supply of its AI-powered chest screening solution, Lunit INSIGHT CXR, to several key institutions in the Philippines and South Korea military.

November 9, 2023
·
2 min read
Drug Development

Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

Artax Biopharma, Inc. announces that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted clinical trial authorization to evaluate AX-158 in a Phase 2a psoriasis study.

November 9, 2023
·
4 min read
Drug Development

Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today announced the initiation of a randomized Phase 2 trial to evaluate the efficacy and safety of TTX-030, a potential first-in-class, anti-CD39 antibody.

November 9, 2023
·
2 min read
Business

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.

November 9, 2023
·
14 min read